Calendar

««Mar 2010»»
SMTWTFS
  123456
78910111213
14151617181920
21222324252627
28293031
  More

Search Box

 

cbt and mindfulness

Mailing List

RSS Feeds








Add to Jamespot
Widgetize!

Translate

Disclaimer

All content within Anxiety Insights is provided for general information only, and should not be treated as a substitute for the medical advice of your doctor or other health care professional.

Anxiety Insights is not responsible or liable for any diagnosis made by a reader based on the content of this website.

Anxiety Insights is not liable for the contents of any external internet sites listed, nor does it endorse any commercial product or service mentioned or advised on any of the sites.

Always consult your doctor if you are in any way concerned about your health.

Recommended links

Depression is Real's Down & Up Show
Weekly audio-casts from the Depression Is Real Coalition

Teen Drug Abuse Intervention
Help fight teen drug abuse, we provide information to help fight teen drug abuse by prevention and intervention.
www.teendrugabuse.us


we support

Kiva.org - micro loans that change lives

Moving a Nation to Care : Post Traumatic Stress Disorder and America's Returning Troops, by Ilona Meagher

No Longer Lonely.com

"just don't smoke"


"Don't smoke, whatever you do, just don't smoke."
                        Yul Brynner

Hit Counter

Total: 3,603,933
since: 14 May 2006

Abstract: First-trimester use of paroxetine [Paxil®] and congenital heart defects

posted Friday, 4 December 2009

Birth Defects Res A Clin Mol Teratol. 2009 Nov;doi:10.1002/bdra.20641

First-trimester use of paroxetine and congenital heart defects: A population-based case-control study

Bakker MK, Kerstjens-Frederikse WS, Buys CH, de Walle HE, de Jong-van den Berg LT.

Eurocat Northern Netherlands, Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; Department of Genetics, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; Department of Pharmaco-epidemiology and Pharmaco-economy, University of Groningen, Groningen, The Netherlands

BACKGROUND: There is a need for case-control studies of the effect of paroxetine on the occurrence of specific heart defects.

METHODS: We performed a case-control study with data from a population-based birth defects registry in the Netherlands. All the children born between 1997 and 2006 were selected. Cases were defined as fetuses and children with isolated heart defects, and the controls were fetuses and children with a genetic disorder with no heart defect. We excluded children for whom there was no information on maternal medication use and deceased children and fetuses who were not examined postmortem. First-trimester exposure to paroxetine was compared between cases and controls by calculating adjusted odds ratios (AOR).

RESULTS: We included 678 cases with isolated heart defects and 615 controls. The first trimester exposure rate was 1.5% for cases and 1.0% for controls. After excluding mothers who used paroxetine outside the first trimester, or who had used another SSRI, we found no significantly increased risk for heart defects overall (10 exposed cases; AOR, 1.5; 95% confidence interval [CI], 0.5-4.0), but we did find a significantly increased risk for atrium septum defects (three exposed cases; AOR, 5.7; 95% CI, 1.4-23.7).

CONCLUSIONS: Our results suggest that the use of paroxetine in early pregnancy is associated with an increased risk of atrium septum defects. The results stress the importance of studying possible teratogenic effects of a drug, preferably in regard to well-specified malformations.

Source...


Copyright © 2009 Wiley-Liss, Inc., A Wiley Company

tags:  

links: digg this    del.icio.us    technorati    reddit